Akamis Bio is a clinical-stage oncology biotechnology company developing tumour-targeted immunotherapies for colorectal cancer and other solid tumours. Its proprietary T-SIGn platform uses systemically administered oncolytic immuno-gene therapies designed to attack tumour tissue and deliver immune-modulating payloads directly into the tumour microenvironment. The company’s lead programme, NG-350A, is being evaluated in clinical trials for locally advanced rectal cancer and other advanced epithelial cancers. Akamis Bio’s work spans drug discovery, translational research, clinical development and strategic collaborations with cancer research and immuno-oncology partners, aiming to create new treatment options that improve patient outcomes and reduce the need for invasive interventions.
This is a company profile stub. Create an account to claim your profile.
Industry
BiotechnologyAreas of Focus
Location
England
Status
Active
